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In vivo genome editing represents an emerging ﬁeld in the treatment of monogenic disorders, as it may
constitute a solution to the current hurdles in classic gene addition therapy, which are the low levels and
limited duration of transgene expression. Following the introduction of a double strand break (DSB) at
the mutational site by highly speciﬁc endonucleases, such as TALENs (transcription activator like effector
nucleases) or RNA based nucleases (clustered regulatory interspaced short palindromic repeats - CRISPR-
Cas), the cell's own DNA repair machinery restores integrity to the DNA strand and corrects the mutant
sequence, thus allowing the cell to produce protein levels as needed. The DNA repair happens either
through the error prone non-homologous end-joining (NHEJ) pathway or with high ﬁdelity through
homology directed repair (HDR) in the presence of a DNA donor template. A third pathway called
microhomology mediated endjoining (MMEJ) has been recently discovered. In this review, the authors
focus on the different DNA repair mechanisms, the current state of the art tools for genome editing and
the particularities of the retina and photoreceptors with regard to in vivo therapeutic approaches. Finally,
current attempts in the ﬁeld of retinal in vivo genome editing are discussed and future directions of
research identiﬁed.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Inherited retinal dystrophies are a group of disorders with a
prevalence of 1 in 3e4000 people (Hartong et al., 2006). Owing to
the complexity of the visual system, several hundred proteins are
more or less uniquely expressed in the retina, andmutations in over
200 genes have been associated with retinal dystrophies (https://
sph.uth.edu/retnet/) (Berger et al., 2010). Speciﬁc advantages of
the eye as target tissue have positioned this organ at the forefront of
gene therapeutic development over the last 20 years, be it gene
addition therapy by use of viral vectors for the transfer of correct
cDNA copies of mutated genes, or gene silencing using RNA inter-
ference to knock down proteins with dominant negative effects or
toxic gain of function activities. In addition, exon skipping ap-
proaches to neutralize mutations in single exons or the expression
of neuroprotective proteins to keep photoreceptor cells alive as
nonspeciﬁc gene therapy approach have been tested (for review of
recent advancements (see Petit et al., 2016).
The very active ﬁeld of retinal gene addition therapy has
advanced the most with several clinical trials ongoing for RPE65
and MERTK deﬁciency (associated with mutations in the RPE65 or
MERTK gene), choroideremia associated with mutations in REP1,
Stargardt macular dystrophy associated with mutations in ABCA4,
juvenile retinoschisis associated with mutations in RS1, and Usher
syndrome 1B associated with mutations in MYO7A (Boye et al.,
2013). For one entity, RPE65 deﬁciency, a treatment based on re-
combinant adeno-associated virus (AAV) vectors expressing the
human RPE65 cDNAunder the control of a viral promoter is about to
reach approval by the FDA and EMA, emphasizing the relative
success with this treatment (Schimmer and Breazzano, 2015).
However, all these approaches aim at neutralizing the symp-
tomatic problem, that is the lack of a given protein production in
case of a nonsense mutation or the production of a non-functional
protein in case of a missense mutation, but leave the cause unad-
dressed, i.e. the disease causing mutation. Furthermore, some
autosomal dominant diseases are caused by gain-of-function mu-
tations that are not addressed by gene addition therapy. What's
more, artiﬁcial expression systems employing viral promoters and
polyadenylation signals without intracellular sensor very likely do
not lead to physiological levels of protein production, which may
hinder the cell to reach the optimal equilibrium of protein levels.
Not to mention the effect proteins expressed from genes with
missense mutations may have on the production rate or function of
transgenic proteins.
Targeted genome editing may solve these issues by correcting
the disease causing mutationwithin the genome in order to restore
the “wild type” DNA sequence of a given gene, enabling the cell to
produce what is needed to have optimal phenotypic outcome (Cox
et al., 2015). Genome editing is based on the cells' own capacity torepair DNA double strand breaks (DSB), which are the most
dangerous form of DNA damage that can occur to a cell. Frequently
happening during mitosis in case of a stalked replication fork or
ionic radiation, DSBs are repaired either by sticking the DNA ends
together by a mechanism called nonhomologous end-joining
(NHEJ), or by use of the sister chromatid as template DNA via ho-
mology directed repair (HDR) (Jasin and Haber, 2016). A third way
to repair DSB represents a mechanism called micro-homology
mediated endjoining (MMEJ). While DSBs occur sporadically and
throughout the entire genome (Lindahl, 1993), the frequency of
DSBs can be dramatically increased and targeted to a deﬁned locus
within the genome by use of sequence speciﬁc endonucleases, such
as Meganucleases, zinc ﬁnger nucleases (ZFN), transcription
activator-like effector nucleases (TALEN) or RNA based nucleases
(clustered regularly interspaced short palindromic
repeats ¼ CRISPR based systems). By use of DNA templates con-
taining homologous DNA sequences at both ends, endonuclease
based genome editing is currently used to rapidly generate animal
models or insert/remove DNA sequences or genes from hemato-
poietic cells ex vivo in human clinical trials (Osborn et al., 2016).
The idea of using targeted genome editing to repair disease
causing mutations is comparatively young, and relies on highly
speciﬁc endonucleases and the capacity of the cell to repair DSB.
Overall, the development of therapeutic strategies leads currently
into two directions: (i) ex vivo genome editing, and (ii) in vivo
genome editing (Fig. 1). Ex vivo approaches are based on the idea to
take a skin biopsy, de-differentiate the cells into induced pluripo-
tent stem cells (iPSCs), correction of the mutation by gene transfer,
re-differentiation of selected cells into RPE or photoreceptor cells
and re-implantation of these cells into the retina. Here, the cells to
be modiﬁed by genome editing re-enter cell division and can thus
be much more easily treated, screened and selected for successful
genome editing.
Alternatively, in vivo approaches aim at treating the mutations
directly in retinal cells in situ. There is no need for ex vivo de-
differentiation, re-differentiation and re-implantation. Vehicles
for in vivo gene transfer exist in form of virus based vectors, such as
AAVs. Themajor drawback here is the post-mitotic state of the cells,
which very likely hinders efﬁcient genome editing, and the absence
of screening and selection possibilities. It is therefore absolutely
necessary to know what we do when modifying the genome in
order to avoid unwanted side effects due to the treatment.
Taken together, in vivo genome editing in the retina involves
several steps that are unique or particularly difﬁcult to establish
(summarized in Fig. 2) compared to other organs, making the entire
concept highly risky. At the same time, the advantages of such a
system for the treatment of many different monogenic disorders
make it worth taking a large effort to bring it to reality.
In this review, the authors focus on the different DNA repair
Fig. 1. General Scheme of genome editing in the retina, distinguishing ex vivo and in vivo approaches.
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and the particularities of the retina and photoreceptors with regard
to in vivo therapeutic approaches. Finally, current attempts in the
ﬁeld of in vivo genome editing in the retina will be discussed and
future directions of research identiﬁed.
2. The tools
2.1. Endonucleases
Genome editing is advancing at an exceptionally rapid pace,
with huge impacts on biotechnology and biomedicine. Trigger for
this revolution was the research transition from companies and
specialized laboratories using engineered meganucleases and
designed zinc ﬁnger nucleases as tools to virtually any molecular
biology laboratory with the introduction of the TALEN and CRISPR/
Cas technology. This groundbreaking development was facilitated
by the dissemination of plasmids harboring these new tools to the
research community by nonproﬁt organizations like addgene. All
tools initiate the genome editing process usually by the introduc-
tion of DSBs or single strand breaks (nick), whose subsequent repair
results in the genomic modiﬁcation. This was ﬁrst demonstrated in
the early-1990s using the highly speciﬁc homing endonuclease I-
SceI (Puchta et al., 1993; Rouet et al., 1994). These results launched
the run for customized nucleases, of which I-SceI, recognizing an 18
bp long sequence, remained the gold standard for cleaving genomic
DNA.
2.1.1. Meganucleases
To exploit the highly speciﬁc LAGLIDADG homing endonucle-
ases, also called meganucleases, for gene targeting, their DNA
recognition properties (14e40 bp) had to be redesigned to cleave
any given sequence (Silva et al., 2011; Stoddard, 2014). Combina-
tions of computational redesign, in vivo selection, artiﬁcial dimers
and high-throughput screening procedures were used to generate
meganucleases with tailored speciﬁcities (Ashworth et al., 2006;
Smith et al., 2006; Pingoud and Wende, 2011; Takeuchi et al.,
2015). Based on I-CreI as a scaffold, naturally binding a palin-
dromic sequence of 22 bp, meganucleases were engineered totarget the mutated human XPC gene in xeroderma pigmentosum
(Redondo et al., 2008), the human RAG1 gene in severe combined
immunodeﬁciency (SCID) (Grizot et al., 2009) or the HSV-1 virus
(Grosse et al., 2011). The extraordinary effort required to retarget
the recognition sequence of meganucleases is responsible for their
drop in importance for genome editing. New approaches make use
of the natural meganucleases in combination with auxiliary, pro-
grammable DNA binding domains, like TALE repeat arrays, ensuring
utmost DNA cleavage speciﬁcity (Beurdeley et al., 2013; Boissel
et al., 2014).
2.1.2. Zinc ﬁnger nucleases
Zinc ﬁnger nucleases were the ﬁrst tools for genome editing
exploiting a bipartite architecture consisting of a DNA-binding
domain fused to a nuclease domain, usually FokI (Kim et al., 1996;
Bibikova et al., 2001; Chandrasegaran and Carroll, 2016).
The DNA-binding domain typically contains an array of three to
six Cys2-His2 zinc ﬁngers. Each ﬁnger is composed of about 30
amino acid residues in a conserved bba-fold and recognizes 3e4
base pairs of the DNA target by using four key amino acid residues.
The combination of different zinc ﬁngers allows to generate zinc-
ﬁnger arrays capable of targeting nearly any desired sequence.
Themain drawback of the simplemodular combination approach is
that the speciﬁcities of individual zinc ﬁngers are context depen-
dent and usually overlap. To compensate the context-dependent
interactions, alternative strategies like OPEN (Maeder et al., 2008)
or CoDA (Sander et al., 2011) were developed to select for highly
speciﬁc zinc ﬁnger arrays. Common zinc ﬁnger nucleases utilize the
nonspeciﬁc catalytic domain of the type IIS restriction endonu-
clease FokI. This domain does not contribute to binding speciﬁcity
but has to dimerize for DNA cleavage (Bitinaite et al., 1998). To allow
cleavage domain dimerization, two individual zinc ﬁnger domains
must bind to opposite strands of the DNA in an inverted orientation
usually separated by ﬁve to seven nucleotides (Fig. 3). To reduce off-
target cleavage, it is essential to use engineered obligatory heter-
odimeric FokI cleavage domains (Miller et al., 2007; Szczepek et al.,
2007). A typical zinc ﬁnger nuclease, as depicted in Fig. 3, recog-
nizing an 18 bp long sequence can confer speciﬁcity within 418 base
pairs, but targets are conﬁned to sequences composed of triplets
Fig. 2. Summary of key steps needed to be optimized to achieve successful genome editing in the retina. Initially, all necessary items for genome editing (i.e. endonuclease,
template, modifying agents) need to be transferred to the target cells, which is usually realized by either subretinal or intravitreal injection of vector suspensions (A, B). Target cells
in the retina are most often RPE and photoreceptor cells (C) (kindly provided by U. Wolfrum, Johannes Gutenberg-University, Mainz). Once, all items are expressed or present in the
target cells, the DNA double strand break (DSB) is induced by the nuclease and repaired by use of the template (D). Nuclease and template will be eventually degraded, thus leaving
nothing behind. Scale: 20 mm.
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approximately every 500 bp. However, zinc ﬁnger nucleases tar-
geting a wide range of different genes have been constructed and
successfully tested (Urnov et al., 2005; Carroll, 2008; Urnov et al.,
2010; Rahman et al., 2011; Gaj et al., 2013).
Despite the modular structure of the zinc ﬁnger binding arrays,
still great efforts are necessary to generate customized highly
speciﬁc zinc ﬁnger nucleases with a reasonable off target activity
(Schierling et al., 2012). Nevertheless, highly evolved zinc ﬁnger
nucleases are the only genome editing tools that are currently
tested as therapeutic agents in clinical trials for the treatment of
Hemophilia B, Mucopolysaccharidosis I and HIV infections (Tebas
et al., 2014) (www.clinicaltrials.gov).2.1.3. TALEN (transcription activator-like effector nucleases)
TALEN closely resemble the zinc ﬁnger nucleases, but make use
of an advantageous DNA binding module derived from transcrip-
tion activator-like effector proteins of the bacterial plant pathogen
Xanthomonas. These proteins are comprised of a central DNA
binding region of tandem repeats. Each repeat usually is 34 amino
acid residues long, with a nearly identical sequence, except amino
acid residues at position 12 and 13, also referred to as repeat var-
iable diresidues (RVD) (Scholze and Boch, 2011). Each repeat me-
diates the recognition of one base in a sequential manner with the
speciﬁcity being determined by the RVD. In 2009, Boch et al. pub-
lished this one repeat - one base relationship as “Breaking the Code
of DNA Binding Speciﬁcity …” (Boch et al., 2009). The modular
Fig. 3. Description of the currently most often used endonucleases and potential repair pathways. (A) Schematic drawing of the three currently used endonucleases. In
turquoise, the DNA binding domains are represented, in yellow the DNA cutting proteins. The length of the DNA recognition sequence is depicted below each cartoon. (B) Three
major different repair pathways exist to repair a DNA double strand break in eukaryotic cells. Each pathway is brieﬂy described in the corresponding carton including the potential
result of the DNA repair. Other mechanisms may also be involved.
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context-dependent interactions between the repeats, enabled the
design of tailored DNA binding arrays from the scratch. For genome
editing, the TALE array is combined with a nuclease domain,
consequently replacing the zinc ﬁngers (Fig. 3). Apart from the FokI
as a cleavage domain (Christian et al., 2010; Miller et al., 2011),
other speciﬁc nucleases (Gabsalilow et al., 2012; Yanik et al., 2013;
Boissel, Jarjour et al., 2014) or effector proteins (Maeder et al., 2013;
Scott et al., 2014; Kungulovski and Jeltsch, 2015) can be fused to the
TALE array, creating a universal platform for highly speciﬁc DNA
targeting. Methods, like the “Golden Gate” cloning system (Cermak
et al., 2011), solid-phase assembly methods (FLASH (Reyon et al.,
2012),) or ligation-independent techniques (Schmid-Burgk et al.,
2015) facilitated the efﬁcient assembly of custom TALE arrays
planed by web-based software (Doyle et al., 2012) and contributed
to the increasing prevalence of TALE based genomic editing (Kühn
et al., 2016). One disadvantage for the delivery of paired TALE nu-
cleases is their size and their repetitive sequences, making it
challenging to utilize viral systems (Holkers et al., 2013). Codon
diversiﬁcation between the repeats mitigated this issue and the
delivery of TALENs with lentiviral and adenoviral vectors have been
successfully demonstrated (Yang et al., 2013b; Holkers et al., 2014).
For therapeutic approaches, one signiﬁcant event in 2015 was the
ﬁrst-in-man application of TALEN engineered universal CAR19 T-
cells in case of a pediatric acute B lymphoblastic leukemia (Qasim
et al., 2015).2.1.4. CRISPR/Cas
In the last century, restriction endonucleases, which represent a
defense mechanism of bacteria against invading viruses, led to the
development of recombinant DNA technology (Roberts, 2005).
Today, another prokaryotic adaptive immune system (Gasiunas
et al., 2014), in particular the Cas9 nucleases belonging to the
CRISPR system type II, revolutionizes genome editing (Doudna and
Charpentier, 2014). Distinct from the other genomic editing tools,
the Cas9 endonuclease is guided via an RNA molecule to its target
site (Fig. 3). Consequently, genome editing can be easily directed to
virtually any genomic site by delivering the complementary RNA
along with the Cas9 endonuclease.
In bacteria, the CRISPR system cuts out small fragments (~20 bp)
from invading virus or plasmid DNA and integrates them as pro-
tospacer between short palindromic repeats in the CRISPR array.
Subsequently, the repeat CRISPR array is transcribed and the RNA
fragments (crRNA) corresponding to the individual integrated
foreign DNA fragments will be excised and integrated in the Cas9
endonuclease with the help of a bacterial trans-activating crRNA
(tracrRNA). This activated Cas9 endonuclease can speciﬁcally cleave
DNA sequences complimentary to the crRNA only if an additional
3e5 bp long sequence, the PAM (protospacer adjacent motif), is
present at the 3’-end of the target. The PAM sequence is recognized
only by the Cas9 protein and is not present in the repeats of the
CRISPR array, preventing the cleavage of the bacterial DNA (Horvath
and Barrangou, 2010).
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crRNA and tracrRNA can be combined to one guide RNA (gRNA) and
that engineered gRNA can stimulate targeted DNA cleavage in vitro
(Jinek et al., 2012). The ﬁrst genome editing of mammalian cells
using the CRISPR/Cas system was described shortly after (Cong
et al., 2013; Jinek et al., 2013; Mali et al., 2013b). Since then, an
enormous number of publications demonstrate that CRISPR/Cas
technology was successfully applied for genome editing in an
increasing number of organisms including crops, fruit ﬂy, zebraﬁsh,
frog, monkey, mouse, rat, pig and human.
The CRISPR/Cas technique is extensively used ex vivo to target
genes for gene disruption, addition or correction in all kinds of cells
comprising embryonic stem cells or zygotes to generate animal
models (Mei et al., 2016). One particular feature of the CRISPR/Cas
system is to target simultaneously several sites in the genome by
using multiple gRNAs (Cong et al., 2013). This potential was
exploited e.g. by the Church lab for a genome-wide inactivation of
62 porcine endogenous retroviruses to reduce transplant immu-
nogenicity for xenotransplantations (Yang et al., 2015). Reports of
somatic gene editing of adult animals by CRISPR/Cas, using viral
vectors or hydrodynamic injection for delivery, are still rare (Platt
et al., 2014; Xue et al., 2014; Swiech et al., 2015; Wang et al.,
2015; Weber et al., 2015; Nelson et al., 2016; Tabebordbar et al.,
2016).
2.1.5. Off-target analysis
Since the ﬁrst genome editing studies were published, the
concern of off target toxicity was eminent. If the endonuclease is
not sufﬁciently speciﬁc for the desired target site, DSBs can be
induced at other locations within the genome, thus leading to toxic
effects and death of the cells. Initially, this toxicity was studied by
cell viability assays such as the propidium iodide cytotoxicity assay,
in which a higher number of stained (i.e. death) cells indicate
increased toxicity of the tested endonuclease (Greenwald et al.,
2010). Also, viability was studied in cells expressing GFP and
transfected with the nuclease of interest. After 3e5 days, the
number of living cells was counted by FACS and compared to non-
transfected cells (Yanik et al., 2013). If the number of GFP positive
cells was signiﬁcantly lower compared to controls, the nuclease
caused a toxic effect to the cells. More recently however, the po-
tential of next generation sequencing was discovered to examine
off-target toxicity, such as by the use of the guide seq method to
study off-target site for the CRISPR/Cas9 system (Tsai et al., 2015).
One constrain for the CRISPR/Cas cleavage is the presence of the
correct PAM in the target DNA. Most studies take advantage of the
ﬁrst described Cas9 nucleases from Streptococcus pyogenes,
recognizing the PAM sequence NGG. Nowadays, Cas9 nucleases
from other origins (Ran et al., 2015; Haeussler and Concordet, 2016)
or with newly engineered PAMs (Kleinstiver et al., 2015) are
available, extending the repertoire of potential target sequences.
Selecting the right target sequence and the corresponding gRNA is
crucial for efﬁcient and speciﬁc cleavage. Web-based resources
predict gRNA efﬁciency and also potential off-targets (Doench et al.,
2016; Haeussler and Concordet, 2016). Moreover, truncated gRNA
with only 17 or 18 nucleotides of complementarity cleave the
intended target site with higher efﬁciency and reduce off-target
effects (Fu et al., 2014). Also other strategies to reduce genome-
wide off-target cleavage of the Cas9 nuclease have been
described: using pairs of Cas9 nickases with only one active center
(Mali et al., 2013a; Ran et al., 2013), pairs of catalytically inactive
Cas9 nucleases fused to the non-speciﬁc FokI nuclease (Guilinger
et al., 2014; Tsai et al., 2014) or rationally engineered high preci-
sion Cas9 nucleases (Kleinstiver et al., 2016; Slaymaker et al., 2016).
It seems that the Cas9 protein alone is not harmful for cells, as
shown by the Zhang lab, producing a CRISPR-Cas9 knockin mouse(Platt et al., 2014), with no obvious abnormal health effects after 20
generations.
Despite recent advances to avoid off-target cleavage, which can
cause unwanted gene mutations or chromosome rearrangements,
an unbiased sensitive whole-genome off-target analysis (Yee, 2016)
in the targeted cell type is indispensable to evaluate candidate
nucleases for clinical applications (Corrigan-Curay et al., 2015).
With the improved CRISPR/Cas systems and TALENs we now
have powerful tools for genome editing, shifting the bottleneck on
the way to the clinical applications to safe and effective delivery
vectors and the promotion of the intended repair pathway.
2.2. DNA repair mechanisms
There are two main pathways in DNA double strand repair
break: HDR and NHEJ. Furthermore, NHEJ is divided into classical
NHEJ (C-NHEJ) and alternative NHEJ (A-NHEJ), also called
microhomology-mediated end joining (MMEJ). NHEJ takes place
during the whole cell cycle, whereas HDR is only present in S- and
G2-phase, when the sister chromatid can act as a template (Lieber,
2008). Therefore, the cell cycle phase and CDKs (cyclin-dependent
kinases) play crucial roles in the pathway choice decision (Ceccaldi
et al., 2015). Frequently, a double strand break occurs following
ionizing radiation or indirectly through chemical modiﬁcations
causing alterations of the replication fork (Pfeiffer, 2000). By
employing endonucleases, targeted DSB can be introduced in a
therapeutic setting (Jasin and Haber, 2016). A short description of
DSB recognition and the different repair pathways is given in the
following section (Fig. 4).
Initially, the DSB is recognized and bound by ATM (Ataxia tel-
angiectasia mutated) and ATR (Ataxia telangiectasia and Rad3-
related protein). These serine/threonine-kinases lead to a fast
phosphorylation of H2AX, then called gH2AX. H2A is one of the ﬁve
major histone families organizing the eukaryotic DNA into chro-
matin. gH2AX can be used as a DSB marker. It plays a crucial role in
recruiting checkpoint factors and others to the DSB, like MDC1
(Mediator of DNA damage checkpoint protein 1) (Yuan et al., 2010).
Through binding of the mediator protein MDC1, the E3 ubiquitin
protein ligase RNF8 (ring ﬁnger protein 8) is activated. This leads to
the ubiquitinylation of H2AX. The reaction is also enhanced by
RNF168 (ring ﬁnger protein 168) (Brandsma and Gent, 2012). It
results in recruitment of 53BP1 (p53 binding protein 1) and RAP80
(receptor-associated protein 80) (Stewart et al., 2009).
RAP80 binds BRCA1 (breast cancer 1), which leads either to
MMEJ or HDR. In contrast, 53BP1 results in binding factors, which
are part of the NHEJ pathway (Ward et al., 2003; Ginjala et al.,
2011). These two molecules, BRCA1 and 53BP1, are known to
form foci at DSB sites (Manis et al., 2004). The current under-
standing is that proteins from both repair pathway machineries
compete for the free DNA ends. How the decision is made by the
cellular repair machinery for a given pathway is currently largely
unknown. Important factors in the decision making process
represent the cell cycle stage and the presence of a template DNA.
2.2.1. Non-homologous end joining
NHEJ is responsible for fast DSB repair. The ends of a DSB are
directly ligated, which can lead to small insertions, deletions or
substitutions. Hence, NHEJ is generally deemed to be an error-
prone DSB repair pathway. It starts by binding of the Ku70/Ku80
heterodimer at sites which are marked by DNA damage sensing
proteins (Fig. 4). Ku is a prominent protein in the human protea-
some (about 400,000molecules per cell) and has a strong afﬁnity to
DNA ends, which are consequently stabilized. The heterodimer
forms an asymmetric ring, interacts with the DNA backbone and
therefore encloses the double stranded DNA independently of the
Fig. 4. Description of the proteins involved in the different repair pathways and
their sequential appearance at the target site. Upon a DNA double strand break, DNA
damage sensing proteins (enveloped in grey) are attracted to the site and process the
DNA ends. During this stage, the decision of a given repair pathway very likely takes
place. Eventually, either homology directed repair (HDR, proteins in green), micro-
homology mediated endjoining (MMEJ, proteins in turquoise, also called alternative (a)
NHEJ), or non-homologous endjoining (NHEJ, proteins in blue, also called classic (c)
NHEJ) will be lounged to repair the DSB. Inhibitors of certain proteins are highlighted
in grey with a grey line pointing to the target molecule.
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then recruits DNA-PKcs (DNA-dependent protein kinase catalytic
subunit). Together they form a huge complex, named DNA-PK. The
DNA end processing is regulated through the autophosphorylation
of DNA-PKcs (Chan et al., 2002). Subsequently, the protein is inac-
tivated and dissociates from the DNA. Furthermore, WRN (Werner
syndrome ATP-dependent helicase) and the nuclease Artemis are
phosphorylated and activated (Karmakar et al., 2002). They are
responsible for the DNA end processing. After completing this
process, the polymerases l and m add missing nucleotides (Fan and
Wu, 2004; Schipler and Iliakis, 2013). The ﬁnal step is the ligation of
the DNA DSB ends via the ATP-dependent LIG4 (DNA Ligase IV),
XRCC4 (X-ray repair complementing defective repair in Chinese
hamster cells 4) and XLF (Nhej1, nonhomologous end-joining factor
1) which form a complex (Povirk, 2012).
2.2.2. Microhomology-mediated end joining
The alternative pathway to the classical NHEJ is MMEJ, for which
still some mechanistic details remain unclear. In contrast to NHEJ,
the ends of the DSB are linked via microhomologous domains on
both sites (5e25 nucleotides) of the DSB, which can lead to adeletion at this position (Deng et al., 2014). So far, not much is
known about speciﬁc features these sequences have to contain, but
it is considered that homology needs to be 100%. Interestingly, if a
template DNA is present containing the microhomologous regions,
precise genome editing is possible. MMEJ is Ku- and Ligase 4-
independent, occurs mainly during the S-phase of the cell cycle
and competes with HDR. The MRN-complex, including Mre11
(MRE11A homolog A), Rad50 and Nbs1 (Nibrin), together with CtIP
(C-terminal binding protein (CtBP)-interacting protein) are
responsible for the DNA end processing (Symington and Gautier,
2011). Therefore, these proteins are indispensable for MMEJ just
as for HDR. The proteins process a small number of base pairs and
make the DNA ends available for MMEJ (Truong et al., 2013). The
ends are ligated via DNA ligase 3. The parameters leading to MMEJ
instead of HDR and NHEJ are still unclear (Sinha et al., 2016).
2.2.3. Homology directed repair
In contrast to NHEJ, HDR is a nearly error-free process, because
of the speciﬁc template used for an accurate repair (Heyer et al.,
2010). After recognition of the DSB through DNA damage sensing
proteins (Fig. 4), the MRN complex is recruited. Single stranded
DNA 3’-overhangs are generated through this complex collabo-
rating with EXO1 (exonuclease 1), DNA2 (DNA replication helicase
2 homolog) and CTIP, which was found in budding yeast
(Symington and Gautier, 2011). This process is also called DNA end
resection. The generated overhangs are crucial for the efﬁcient
repair. A region, which is homologous to the overhang, is used as a
template for the repair. The processing of the DNA at the DSB is in
addition controlled by BRCA1, a well-known tumor suppressor
protein (Daley and Sung, 2014). Subsequently, BLM (Bloom syn-
drome, RecQ helicase-like) and EXO1 recruit RPA1 (replication
protein A1). RPA1 rapidly binds single stranded DNA, stabilizes the
ends and inhibits the formation of secondary structures (Mimitou
and Symington, 2009). After that, RPA1 gets replaced by RAD51.
This protein searches for homologous regions and promotes
together with BRCA2 (breast cancer 2) the accumulation of DNA.
Finally, the ligation of the DNA ends is made by LIG1 (DNA ligase I)
(Holthausen et al., 2010; Yan et al., 2011).
2.2.4. Alternative strategies to edit the genome
While NHEJ is often favored over HDR, especially in human cells,
and because NHEJ is error prone and can lead to mutations or
chromosomal rearrangements, it is important to be able to control
the DNA repair mechanisms or, in the case that HDR of MMEJ is
wanted as editing approach, ﬁnd strategies that most likely do not
employ NHEJ as repair mechanism (Karran, 2000). NHEJ could, in
turn, be employed to knock-out toxic gain-of function alleles in
autosomal dominant diseases.
One way would be to inhibit NHEJ factors by siRNA technology
or speciﬁc blockers (see examples in Fig. 4), which was shown to
result in increased activities of HDR proteins to repair the DSB, a
mechanism further demonstrating the competitive interaction of
the different proteins at the DSB site (Budke et al., 2012; Munck
et al., 2012; Chu et al., 2015; Maruyama et al., 2015; Tadi et al.,
2016). It remains to be seen how useful this approach may be in
in vivo applications, where certain drugs may be toxic and therefore
cannot be employed or where siRNA technology may not be
amenable either.
Another possibility is a site-directed single strand break (SSB),
also called nick. Recent work has shown that the cleavage of only
one DNA strand leads to less off-site targeting compared to a DSB
(Metzger et al., 2011). In most cases, the SSB gets repaired by a very
fast global repair process. This process is divided into four steps,
similar to the DSB repair: SSB detection, DNA end processing, DNA
gap ﬁlling and DNA ligation. PARP1 (poly(ADP-ribose) polymerase
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Nicking Cas9 variants with less toxicity were already mentioned in
chapter 2.1.4. Nicking homing endonucleases are a good alternative
due to their small size compared to TALEN or CRISPR/Cas. A com-
parison between the wt homingendonuclease I-AniI (inducing a
DSB) and a nicking variant of I-Anil showed lower HR ratios for the
nicking nuclease by a factor 4 to 6 and also lower mutation rate by a
factor of 150. No severe toxicity was observed (Davis and Maizels,
2011; Metzger et al., 2011).
More recently, a different way of changing a given DNA
sequence has been introduced, the targeted base editing (Komor
et al., 2016). This technology, a fusion between an inactivated
Cas9 protein and a cytidine deaminase allows to change one base
into another (here: C to T) without previous introduction of a DSB
or the use of a template, thus potentially avoiding the complica-
tions associated with DSB repair, in particular the generation of
indels. However, if the treatment goal is to insert or remove bases
from the sequence, this technology cannot be employed.
2.3. Template
The efﬁciency of HDR is determined by many parameters, such
as the cell cycle, the cell type, chromosomal region, the activity of
endogenous repair system, and the DNA donor template. During
the S and G2 phases of the mitotic cell cycle, the homologous
sequence is naturally present as sister chromatid (Heyer et al.,
2010). However, template DNA can also be engineered artiﬁcially
and provided exogenously for repair. For accurate DNA repair by
HDR, an undamaged donor template with sufﬁciently long ho-
mology regions ﬂanking the target site is required. Although
chemical or genetic regulation of repair pathway components andFig. 5. Design of currently available templates. Templates can come as double stranded p
(AAV or IDLV).manipulation of cell cycle can bias the repair outcomes toward HDR
(Srivastava et al., 2012; Chu et al., 2015; Maruyama et al., 2015), it
may be undesirable for therapeutic applications because they can
disturb the function of cellular genes and lead to tumor formation.
Recently, up to 60% HDR rate in HEK cells has been reported by
using Cas9 or nickase variants and single-stranded DNA (ssDNA)
donors in the absence of chemical and genetic intervention
(Richardson et al., 2016). It demonstrates that designing DNA donor
in an appropriate manner plays a central role in increasing HDR
frequencies.
Linearized or double-stranded DNA plasmid sequences, as well
as ssDNA oligonucleotides, are used as template for homologous
recombination at the target site (Fig. 5). The size of the intended
sequence changes, the length of the homology arms, and the
insertion site of the mutation are important factors to be consid-
ered (Carroll and Beumer, 2014). Although the exact mechanism by
which donor design increases HDR frequencies is still under
investigation, several evidences have shown its inﬂuence on gene
targeting outcomes.
In mammalian cells, total homology up to 10 kb increases the
HDR frequencies without even a target cleavage, an observation
that has been widely used for creating gene-targeting vectors for
the generation of animal models (Deng and Capecchi, 1992). In the
presence of an induced DSB at the target site, a plasmid donor with
at least 1e2 kb of total homology is recommended for large
sequence changes more than 100 bp (Dickinson et al., 2013; Yang
et al., 2013a). The cleavage site should be as close to the insertion
site of the mutation as possible, ideally less as 10 bp away. The
efﬁciency of recombination increases as the length of homology
arms increases, while the efﬁciency decreases as the size of the DNA
insert increases (Li et al., 2014). Although linear donor template haslasmid, linearized plasmid, PCR product, single stranded (ss)DNA or viral vector DNA
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cular donor (Carroll, 2011), the higher degradation rate and unde-
sirable spontaneous integration could be critical for genome
stability. SsDNA sequences are usually more efﬁcient than plasmid
donors for small sequence changes up to 50 bp; 30e80 bp of ho-
mology arms on each side ﬂanking the target is preferred (Sakuma
et al., 2016).
One important point to note is that Cas9 behaves differently
from ZNFs and TALENs. SsDNA donors complementary to the non-
target strand showed higher HDR frequencies due to the asym-
metric release of Cas9 from the cleaved DNA strand (Richardson
et al., 2016).
2.4. Vectors for gene transfer
Different delivery systems are available to transfer genes into
the retina. Differences are present with regard to longevity of
transgene expression, immune response by the host organism and
size of the transferred genes, among others (summarized in
Table 1).
In order to perform in vivo genome editing, an expression
cassette containing the genetic information encoding the nuclease
together with a promoter sequence and a polyadenylation signal
needs to be transferred into the target cell. In case the CRISPR/Cas
system is used, an additional expression cassette containing the
guide RNA information with a promoter sequence (usually about
400bp in size) is also needed. If HDR or MMEJ in a therapeutic
setting is envisaged, a template DNA (ranging from 100 to more
than 1000 bp in size, depending on the target sequence to be
repaired) is crucial and needs to be transferred as well. The efﬁcient
transfer of these three items represents one of the major hurdles to
overcome in in vivo retinal genome editing, and the choice of an
optimal vector system is crucial.
Many reviews exist that highlight the different characteristics in
general (Gaj et al., 2015; Nelson and Gersbach, 2016). Here, we
describe the characteristics of the most promising vectors for
genome editing purposes in the retina in vivo.
2.4.1. AAVs
Adeno-associated virus (AAV) is a mammalian single stranded
DNA parvovirus. Its genome consists of about 4.7 kB containing two
inverted terminal repeats (ITRs) ﬂanking genes for replication (rep)
and building the virus capsid (cap). AAVs are known to infect non-
proliferating and proliferating cells (Baba et al., 2012). After infec-
tion of the host cell by receptor mediated endocytosis, the virus
genome persists as episome in the cell. In order to generate a re-
combinant vector, the entire virus sequence except the ﬂanking
inverted terminal repeats are replaced by the expression cassette of
choice. Several recombinant AAV (rAAV) serotypes which are able
to target different cell types have been extensively characterized.
While the AAV serotype 2 was employed as photoreceptor (PR) andTable 1
Vectors used for retinal gene transfer.
AAV LV
Capacity (kB) 4,8 8
Size 20 nm 120 nm
Genome ssDNA ssRNA
Integration No Yes
Clinical trails 12 4
Target cell (Cell speciﬁcity) Dividing and non dividing Dividing and n
Cell entry endocytosis endocytosis
Nuclear entry yes yes
Immunogenicity low lowretinal pigment epithelium (RPE) transducing vector for many
years, the serotypes 5, 8 and 9 have more recently gained higher
importance as transfer vectors to the retina.
Unlike any of the other vehicles which can be used for genome
editing, AAVs were shown to stimulate homologous recombination
in mammalian cells (AAV-mediated gene targeting) by its own
presence in a very efﬁcient way (Gaj et al., 2015). Up to 1% HDR
could be shown in human ﬁbroblasts using AAVs without intro-
duction of a DSB (Russell and Hirata, 1998). The presence of a DSB
increases the efﬁciency by up to 1000 fold (Russell and Hirata,1998;
Gaj et al., 2015). One of the possible reasons for the high HDR ef-
ﬁciency of AAVs is the single stranded nature of the AAV template.
Other potential factors are the nuclear localization of a high num-
ber of genomes and the recombinogenic ITRs (Hirata and Russell,
2000). It is possible to improve the efﬁciency rate of AAV-
mediated gene targeting by increasing the homology arm length,
ﬁnding the best length of homology and locating the target sites
within the transcriptional units (Gaj et al., 2015). Other important
aspects as type of mutation and chromosomal context are more
difﬁcult to inﬂuence (Hirata and Russell, 2000; Hirsch et al., 2010).
When used together with ZFN, rAAV2 based HDR donor templates
resulted in a frequency of 6% HDR in human cells (H€andel et al.,
2012).
Though AAVs are promising vehicles for gene transfer, one main
disadvantage is their maximum cargo capacity of 4.7 kB, which is
not sufﬁcient for some of the nucleases. For example, the currently
used Streptococcus pyogenes (Sp) Cas9 is about 4.2 kb in size and
together with the promoter sequence and its gRNA, it is too large to
ﬁt into a single AAV vector. Therefore, one would need two AAV
vectors (one for the Cas9 gene, and one for the guide RNA
sequence), or one of the other transfer vectors in order to transfer
the genetic information into the target cells. In contrast, the smaller
Staphylococcus aureus (Sa) Cas9 is about 3.2 kb in size and thus, can
be transported together with the guide RNA by one AAV vector
alone (Gaj et al., 2013; Friedland et al., 2015; Ran et al., 2015).
To transfer larger expression cassettes, dual vectors have been
developed, which are based on the ability that AAVs can con-
catamerize by splicing, HDR, or a combination of both (Trapani
et al., 2014a). These trans-splicing vectors have a lower expres-
sion rate than single AAVs (Maeder and Gersbach, 2016), showing
only around 16% protein expression in HEK293 of that transduced
with a single AAV (Xiao et al., 2000). However, mouse models of
Stargardt macular dystrophy and Usher syndrome 1B treated with
these vectors showed a milder phenotype (Trapani et al., 2014a).
The dual vectors were also tested in large cone-enriched pig
retinae, where the transfer-efﬁciency was signiﬁcantly higher than
in mice, but still two-to threefold lower than the transduction rate
achieved by a single AAV vector (Colella et al., 2014). To further
increase the transduction efﬁciency, ITRs with homology to F1
phage seems to be promising (Trapani et al., 2015). Beside mouse
and pig model systems, rAAVs were used to transduce ON bipolarSupercharged proteins Nanoparticles
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was not of great success (Fradot et al., 2011).
Altogether, AAVs are promising vehicles for genome editing
despite their low cargo capacity. They show no immune response
when subretinally injected and are able to express genes in non-
dividing cells like photoreceptors and other neurons.
2.4.2. Lentivirus-based vectors
Lentiviruses are retroviruses with a ssRNA genome that is in-
tegrated into chromosomes of target cells. Because of this random
integration, LVs are not as safe as non-integrating vehicles, but able
to express transgenes for a very long time, especially in constantly
dividing cell populations. To overcome the random integration
issue, an integrase deﬁcient lentiviral vector (IDLV) was developed
(Philpott and Thrasher, 2007). IDLVs have been used in studies with
different human target cells in the context of genome editing. They
seem to be promising vehicles for donor templates in dividing cells,
generating HDR in up to 10% of a given cell population (Chen and
Gonçalves, 2015). Another possibility to ensure that there is no
long term expression of the genome editing tools, which may lead
to off-target activity, is to integrate cleavage sites for the used
cutting enzyme in the vector genome.
One big advantage in contrast to AAVs is that LVs can carry large
transgenes up to 8 kb (Trapani et al., 2014b), although larger
transgenes may yield lower functional particle titers (Kumar et al.,
2001). This characteristic makes LVs suitable to be used to transfer
all kinds of nucleases, including SpCas9 or TALEN fused to restric-
tion enzymes (Fok-I). However, if a large template is needed for
HDR, a second LV may still be needed. Subretinal injection of len-
tiviral vectors pseudotyped with the VSV-G (vesicular stomatitis
virus glycoprotein) results in a strong transgene expression in RPE
cells and to a lower extend in PRs. Differences regarding the
transduction efﬁciency in retinal explant cultures from mice and
human were observed, potentially indicating that transduction
rates may be species speciﬁc (Lipinski et al., 2014).
Since most of the LV pseudotypes are known to transduce
mainly RPE cells in adult retina, Puppo et al. tested 7 LV pseudo-
types for PR transduction. They found LV-GP64 to transduce PR, but
still AAV2/8 achieved a higher efﬁciency (Puppo et al., 2015).
Furthermore, LVs are promising vehicles to transfer genes into
iPSCs because of their stable integrating capability. This was already
shown in a study, in which an expression cassette containing the
correct CEP290 cDNA was stably introduced into iPSC-derived,
photoreceptor precursor cells from Cep290-associated LCA pa-
tients, leading to a stable expression of wt CEP290 protein
(Burnight et al., 2014).
Altogether, LVs have the potential to be used as transfer vectors
for endonucleases and template in treatment approaches for retinal
diseases, even though transduction efﬁciency in PR is limited.
2.4.3. Supercharged proteins
For genome editing purposes, especially using CRISPR/Cas9,
direct transfer of the Cas9 proteins could be of interest, because
there is no ongoing activity of the cutting enzyme needed, or even
undesired due to their potential off target toxicity. However, simple
protein transfer into cells in vivo is very inefﬁcient. One way to
increase transfer efﬁciency is to change the net charge of proteins
making them capable of traversing lipid membranes.
Proteins with very high theoretical positive or negative net
charge are called supercharged proteins. Such proteins are known
to be able to penetrate mammalian cells in vitro and in vivo. Re-
porter proteins like GFP, streptavidin and glutathione S-transferase
have been modiﬁed to act as supercharged proteins. These proteins
can bind to small molecules like DNA or to other proteins, which
results in an electrostatic complex. Like AAVs and LVs,supercharged proteins penetrate cells by endocytosis. Thompson
et al. described that superpositively charged proteins that have a
greater property to transduce mammalian cells than cationic pro-
teins (Thompson et al 2008). Cronican et al. tested supercharged
GFPmolecules (þ36 net charge) in adult mouse retina by subretinal
injection and observed a GFP signal in the entire retina. They also
analyzed if supercharged GFP could transport active Cre recombi-
nase in mouse p0 retina and showed a small amount of functional
enzyme to be delivered into the retinal cells (Cronican et al., 2010).
More recently, another group reported that negatively charged
proteins, containing anionic domains can also be used as vehicles
for protein transfer in vivo. They showed 20% genome modiﬁcation
after transduction of Cas9:sgRNA complexes into mouse inner ear
hair cells (Zuris et al., 2015). Nonetheless, nuclear localization and
target cell speciﬁcity need to be further improved regarding
supercharged proteins, before such an approach may reach clinical
stage.
2.4.4. Nanoparticles
Nanoparticles (NPs) act like DNA-histone complexes, containing
positively charged peptides, bound to a single DNA molecule. They
enter the target cell by binding to the nucleolin receptor and are
transported directly into the nucleus (Chen et al., 2008). A big
advantage of nanoparticles is their capacity to carry up to 14 kB
when used as vehicle in the eye (Han et al., 2012a, b), which would
make them suitable for the transfer of nucleases, guide RNAs and
template all in one vector. Peptides for ocular delivery (POD) can
enter RPE and PR cells in vivo after subretinal injection. Johnson
et al. created a POD-GFP fusion protein and localized it in the nu-
cleus, therefore POD seems to act as an nuclear localization signal
(Johnson et al., 2010). The same group showed a transduction ef-
ﬁciency of 40% of the retinal surface in the ONL.
In direct comparison to AAVs, NPs, which are composed of
polyethylene glycol-substitutes polylysine (CK30PEG) showed
matchable scale and longevity in vivo in mouse retina. Although
NPs are less efﬁcient per vector genome, the gene expression level
is similar to AAVs (Han et al., 2012a, b). Nanoparticles are able to
transduce dividing and non-dividing cells due to their transport
mechanism (Koirala et al., 2013a), the transferred genes remain
episomal and showno toxicity in PR and RPE cells (Han et al., 2012a,
b). In 2012, Han et al. were able to deliver the ABCA4 cDNA with a
size of 6.8 kb packed in NPs (CK30PEG) into Abca4-deﬁcient mouse
PRs. The group showed an expression of the ABCA4 protein for up to
8 month post injection (Han et al., 2012a, b). Another study showed
the possibility to treat RPE cells with a gene of interest which was
too large for AAVs (Koirala et al., 2013b). These studies demonstrate
the big advantage of NPs in comparison to AAVs, regarding the size
of the gene transferred.
Another positive characteristic is that compared to AAVs, NPs
express packed genes faster. To specify the cells which express the
gene transported by NPs, a speciﬁc promotor can be used, for
example rod and cone mouse opsin promoter (MOP) (Han et al.,
2012a, b). The therapeutic effect of the wt peripherin2 gene
packed in NPs were tested in a retinitis pigmentosa mouse model
(rdsþ/-) at P5 and P22. The rod function was improved after
treatment and cone function showed even wt level. The authors
concluded that NPs are able to transduce mitotic and postmitotic
PRs (Cai et al., 2010). Differences could be detected regarding the
types of injection. If ultrapure oligochitosans carrying pCMS-EGFP
were subretinally administrated, RPE and PRs were transduced,
while intravitreal injection caused mainly ganglion cells and some
PR transduction in rat retina (Puras et al., 2013a, b).
Taken together, nanoparticles represent a promising technology
to transfer genes and template to the retina, especially because of
the unlimited size of DNA particles to be transferred and the
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In conclusion, several gene transfer systems are present to
deliver the genetic information that encodes for the endonuclease
together with the template DNA. While AAV vectors, currently
considered the gold standard for retinal gene transfer, may have
signiﬁcant limitations to transport both the genetic information of
the endonuclease and any potential template, theses hurdles can
potentially be overcome by use of other viral vectors or nano-
particles, each having its own limitations. A combined delivery of
the endonuclease as protein and the template within an AAV vector
may be the optimal choice, since protein delivery ensures a tem-
poral burst of endonuclease activity while AAV delivery increases
DNA repair machinery activity by itself.
3. The retina
3.1. Cell culture vs tissue e intermediate model?
Cell cultures are an ideal model to study cellular pathways and
alterations of the cellular machinery since these cells continue to
divide for a long time and are easily modiﬁable in terms of trans-
ferring genetic material and observing metabolic changes. There-
fore, cell culture technologies have been applied to study DNA
repair mechanisms since early on. In fact, most of the current
knowledge about thesemechanisms is based on data obtained from
cell cultures. Not surprisingly, knowledge about the cell cycle
dependent activities of the different repair mechanisms relies on
the capacity of scientists to analyze cells from cell culture systems
at deﬁned stages of mitosis. Not to mention that literally all cells in
a dish are exactly similar, as they represent the result of clonal
ampliﬁcation of a single cell.
When it comes to post-mitotic neurons in general, almost
nothing is known concerning the activity of DNA repair machin-
eries, expression and localization of proteins involved in chromatin
structure, DNA damage sensing and cell cycle reactivation. This gap
in the currently available knowledge represents a signiﬁcant hurdle
in the further development of genome editing strategies for post-
mitotic tissues in general and certainly for approaches regarding
the retina.
Since the retina is a highly structured organ with at least 5
different types of neurons (photoreceptors, bipolar cells, horizontal
cells, amarcrine cells, ganglion cells) and macro- and microglia
cells, it is difﬁcult to generate valid information about the DNA
repair status in each cell type separately. With over 80%, photore-
ceptors represent the vast majority of retinal cells, thus making the
analysis of whole retina lysates meaningful if one considers po-
tential gaps from the remaining cell populations.
Not only the DNA repair pathway situation (reviewed in the next
section) is difﬁcult to assess in retinal tissue, the issue of gene or
protein transfer to the target cells within the retina remains crucial
in the further development of such a treatment approach. In order
to study the impact of genome editing approaches on the different
retinal cells, a good model is needed. That is, apart from in vivo
models, to have a system that allows to easily administer different
molecules to increase or block certain repair pathways, to manip-
ulate the macroenvironment within the tissue (e.g. inducing hyp-
oxia) and observing alteration to the retinal morphology over time.
In our view, the organotypic retina culture system represents an
ideal intermediate system between the cell culture and the com-
plex in vivo situation. Such a systemwas ﬁrst describedmore than a
decade ago (Caffe et al., 2001; Hatakeyama and Kageyama, 2002;
Pang et al., 2004) and usually keeps the retina in a viable state for
at least 10e14 days (Fig. 6). Organotypic retina cultures display
much of their in vivo phenotype in terms of cytoarchitecture and
stratiﬁcation assuming that intercellular connections are preservedas well. The post mitotic character of all different neuronal cell
types is preserved and thus, can be studied in detail. Cell type
speciﬁc targeting can be investigated by application of vectors onto
the photoreceptor side or the ganglion cell side mimicking sub-
retinal or intravitreal injections. In normal neonatal mouse retinae,
the cell transduction properties of AAV1, AAV2 and AAV5 vectors
were compared side-by-side both in vivo and in vitro (Pang et al.,
2008). It was shown at least in the neonatal retina culture that
AAV vectors behave analogously in organ culture and in vivo. In
mature retina culture systems, the transduction efﬁciency is
comparably low, but research is currently undertaken in order to
increase gene transfer efﬁciency (Fig. 7). Therefore, the organotypic
retina culture represents a viable alternative to in vivo assays.
An alternative model system represents the 3D retina culture
(also called organoids) started from iPSCs that eventually form
retinal organoids and reach a layer architecture somewhat similar
to that found in adult retina (Clevers, 2016; Kaewkhaw et al., 2016).
However, in depth analysis of the mitotic state of the cells within
such a culture system needs to be done before it may be used to
model in vivo genome editing approaches.
3.2. DNA repair activity in post-mitotic photoreceptors
With the murine retina being a tissue directly exposed to UV
light (mice possess UV sensitive cones), many people would argue
that the DNA repair machinery is highly active in these cells, given
the fact that the repair of DSBs induced by radiation is crucial for
the maintenance of genomic stability. In contrast, human cornea
and lens are not permeable for UV light, which may result in
different levels of repair activities in human retina. However,
almost nothing is known about the activity of the DNA repair ma-
chinery in PR or RPE cells, be it murine or human. The post-mitotic
state of neuronal retinal cells very likely hinders efﬁcient genome
editing in the retina. Together with the absence of screening and
selection possibilities this is the major draw-back in in vivo genome
editing.
In an early study, whole retina lysates were used to demonstrate
DNA repair activity to correct site speciﬁc mutations in antibiotic
resistant plasmids (Ciavatta et al., 2005). However, this experiment
left un-addressed the differences in cell populations within the
retina. The observed repair activity may have come from bipolar or
ganglion cells, or even retinal glia cells. More recently, a study
nicely demonstrated that especially rod photoreceptors, which
represent the majority of cells in the murine retina, behave differ-
ently to DSBs compared to any other cell type in the retina. Murine
rods have inverted heterochromatin organization, i.e. contain a
single large chromocenter in the middle of the nucleus (Solovei
et al., 2009; Solovei et al., 2013). Interestingly, Frohns and col-
leagues (Frohns et al., 2014) observed that adult rod photoreceptors
repair only half of the induced DSBs within 1 day after damage
induction, a defect that is not observed in any other cell type of the
adult retina nor in rod photoreceptor precursor cells of postnatal
day 4mice. They showed that adult wild-type rods are deﬁcient in a
repair pathway involving ATM, a protein that promotes hetero-
chromatic DSB repair by phosphorylating KAP1 and facilitating
heterochromatin relaxation. Of note, they observed that rods fail to
robustly accumulate active ATM at DSBs, exhibit low KAP1 levels,
and display high levels of SPOC1, a factor that suppresses KAP1
phosphorylation. This leads to dramatically reduced KAP1 phos-
phorylation and the inability to repair heterochromatic DSBs,
which together with the failure to relax heterochromatin could
serve to maintain the distinct heterochromatic structure of rods.
Collectively, these ﬁndings show that the unique chromatin orga-
nization of adult murine rods decrease repair efﬁciency for het-
erochromatic DSBs, providing evidence that heterochromatin
Fig. 6. Organotypic culture of adult murine retina. (A,C) Retina at day 0 of the culture, that is directly after euthanasia of the animal. (B,D) Retina at day 6 in culture. The retinae at
0 and 6 days in culture show comparable morphologic structures in hematoxilin/eosin staining (A,B), as well as when focussing on the photoreceptor terminals (stained with CtBP2
for the presynaptic ribbon structure) or the bipolar cells (stained with PKCa for the bipolar cells surface) (C,D). DAPI staining for visualizing the nuclei. ONL: outer nuclear layer; OPL:
outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer, Scale bar: 50 mm.
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rhodopsin, being the most transcribed gene in photoreceptors,
might be a promising target of gene repair rather than other less
transcribed loci.
Since chromatin organization in rods in humans is different
frommice, it maywell be that the issue of lowDNA repair efﬁciency
levels observed in mice may not be observed in humans. However,
since the mouse routinely serves as model system for the devel-
opment of retinal gene based therapies, scientists should consider
this issue in their experimental setups.
Further work to enable precise gene correction in post-mitotic
cells such as retinal neurons is critical in developing therapeutic
strategies for the numerous inherited dystrophies that are
currently untreatable. The solution to improve HDR in neurons will
likely become evident as we improve our understanding of DNA
damage repair mechanisms in neurons (Cox et al., 2015).
3.3. Neonatal versus adult retina
The adult mammalian retina as part of the central nervous
system consists of terminally differentiated neurons that are in a
post-mitotic state and cannot re-enter the cell cycle. Retinal glial
cells (e.g., astrocytes, oligodendrocytes, and microglia) are in either
a proliferative or non-proliferative state, depending on their dif-
ferentiation status and possible re-entry into the cell cycle (Iyamaand Wilson, 2013). The emergence of different cell types in the
mouse retina occurs in two major waves (Cepko et al., 1994). The
ﬁrst wave peaks at E14.5, giving rise to early forming cell types,
including retinal ganglion cells (RGCs), cone photoreceptors, ama-
crine cells, and horizontal cells. The secondwave peaks at P4, giving
rise to late-forming cell types, including rod photoreceptors, bi-
polar cells, and Müller glia cells. With eye lid opening around P13,
another major change to the neuronal cell phenotype in the retina
takes place, as master regulators of neuronal gene expression
change the global gene expression proﬁle within the retina (Perera
et al., 2015). As a result, photoreceptors and other neurons differ-
entiate into their ﬁnal stage, having a fundamentally different gene
expression proﬁle compared to cell populations at earlier time
points around birth. Hence, during the ﬁrst 3 weeks after birth, a lot
of terminal differentiation of retinal neurons take place, i.e. they
become specialized, taking on speciﬁc structural, functional, and
biochemical properties and roles. In humans, ultimately the target
tissue, maturation and specialization of retinal neurons take place
already in utero and is by and large ﬁnished at birth (Provis et al.,
2013), even further necessitating treatment strategies and model
systems that deal with differentiated neurons, like the adult mouse
retina, in order to generate meaningful data prior to clinical
application.
Electroporation as a method to transfer genes into the retina
only works in neonatal animals (day 0) or embryonic stages,
Fig. 7. Transduction of adult organotypic retina culture with AAV vectors. (A) The method of transduction is to add the vector between the TEPC membrane and the retina ﬂat
mount with the photoreceptors facing the membrane. After 6 days in culture, GFP signalling is visible in photoreceptors as well as some Müller cells (B-F). Long arrows in B-D
indicate photoreceptor nuclei in ﬂat mount preparation. Short arrows in E and F indicate photoreceptor nuclei in retinal sections. ONL: outer nuclear layer; OPL: outer plexiform
layer; IS: inner segments; IPL: inner plexiform layer; INL: inner nuclear layer. Scale bars: 50 mm in B þ F, 10 mm in C þ D.
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molecules during cell division. Electroporation has been effective in
animals for plasmid and siRNA delivery to the embryonic or
neonatal retina (Matsuda and Cepko, 2004; Matsuda and Cepko,
2007; Sanuki et al., 2011). It produced lasting expression of GDNF
and GFP in the retina after neonatal gene transfer (reviewed in
(Bloquel et al., 2006). However, since targeted in vivo genome
editing to repair disease causing mutations is likely to take place in
fully differentiated, (i.e. mature) retinal neurons in vivo, gene
transfer via electroporation is currently not a realistic way, and
research using embryonic or neonatal animal models are not the
proper experimental setting to test highly speciﬁc endonucleases
and the capacity to bias the repair pathways towards HDR.
4. Preclinical approaches
Since in vivo approaches to treat genetic disorders have partic-
ular hurdles to overcome, information from studies not related to
the retina but having been performed in vivo in the mouse can
highlight current advancements in the ﬁeld of genome editing. For
example, the recent success in correcting disease causing muta-
tions in the DMD gene encoding the dystrophin protein, causing
Duchenne muscular dystrophy (DMD), shows the potentials of
in vivo genome editing. The removal of exon 23 by in vivo genome
editing using an AAV vector expressing CRISPR/Cas9 in a mouse
model of DMD led to improved muscle function in the absence of
signiﬁcant off-target toxicity proofed with deep sequencing
(Nelson et al., 2016; Tabebordbar et al., 2016).
Of course, cell cultures are optimal to start with when thinking
about a given treatment strategy based on genome editing. One can
easily design and test TALEN constructs or verify whether CRISPR/
Cas9 mediated genome editing causes off target toxicity. This was
done originally by several groups to test the usefulness of ZFNbased genome editing approaches at the rhodopsin (Greenwald
et al., 2010) or the Usher Syndrome 1 C (Overlack et al., 2012) lo-
cus. In both cases, signiﬁcant activity of the designed endonucle-
ases was observed in modiﬁed cell lines harbouring speciﬁc
mutations that were addressed by the endonucleases, and off-
target toxicity was marginal as veriﬁed by cell viability assays.
More recently, patient derived induced pluripotent stem cells
are used to study genome editing, such as in cells derived from
patients with XLRP, in which the disease causing mutation was
repaired by use of the CRISPR/Cas9 system (Bassuk et al., 2016). In-
depth off-target analysis was not performed so far. The idea of
generating patient derived stem cells in order to correct the disease
causing mutation and the use of these corrected cells to study
potential treatment effects or even re-implant them into the pa-
tient's retina is the basis of the ex vivo genome editing approach,
which has been reviewed extensively elsewhere (Wiley et al.,
2015).
Working in vivo, the ﬁrst approach often tested is to introduce
organ or tissue speciﬁc changes to the genomewhile proﬁting from
the advantages of dividing cells through modiﬁcation of fertilized
oocytes to generate founder animals that contain the altered
sequence. This was done at the rd8 locus in the murine genome,
which is a common defect in all mouse lines generated from the
C57BL/6NJ line and which complicates phenotypic analysis of new
strains because of its own impact on the mouse retina (Low et al.,
2014). Single stranded oligonucleotides together with TALEN
mRNA were co-injected into oocytes, resulting in up to 27% of
corrected alleles in live-born animals. Frequency of Off-target
toxicity events was as low as 4%, as analysed with a SNP assay to
detect illegitimate recombination. A similar approach was used in
rd1 mice, where the two different mutations were addressed by
CRISPR/Cas9 mediated genome editing using microinjection of
gRNA, single stranded oligonucleotides and Cas9 protein into
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eration (Wu et al., 2016).
While both approaches do represent genome editing ap-
proaches in the visual system in living animals, they do not
represent what we consider in vivo genome editing approaches (i.e.
gene transfer to the retina and gene correction in situ). The ﬁrst
approach that does ﬁt the deﬁnition of in vivo genome editing was
published by Chan and colleagues in 2011, when they studied the
effect of I-SceI mediated genome editing in adult ID2-hRho-GFP
knock-in mice following AAV2/5 mediated gene transfer at 3e4
weeks of age (Chan et al., 2011). At 24 weeks post subretinal in-
jection, several hundred rods were successfully repaired to express
GFP (template was a duplicated segment within the target site) in a
deﬁned area of the injected zone, representing about 15% of all
transduced rods within the same injected zone. Alterations at the
target site were observed in almost all transduced rods, indicating
that the repair machinery in adult rods is able to perform NHEJ as
well as HDR with considerably high frequencies. No off-target
analysis was performed in this study.
In a more recent study, a dual AAV2 vector system was used to
transfer SpCas9 (ﬁrst vector) and gRNA against YFP together with
an mCherry expression cassette (second vector) to the retina of the
Thy1-YFP mouse line via intravitreal injection with the aim to
disrupt the YFP signal in the inner retina (Hung et al., 2016). Ani-
mals were between 14 and 16weeks old at the time of the injection,
and 5 weeks later, only 10% of mCherry positive cells in the inner
nuclear layer were YFP positive, while 70% of mCherry positive cells
were YFP positive in control animals injected with gRNA against
LacZ. No off-target analysis was performed in this study.
Finally, a single subretinal injection of guide RNA (gRNA)/Cas9
plasmid in combination with electroporation at P0 generated
allele-speciﬁc disruption of the murine S334ter allele in the
respective S334ter-3 rat model, which prevented retinal degener-
ation and improved visual function at day 30 (Bakondi et al., 2016).
It should be noted that the speciﬁcity of the approach cannot be
transferred directly into the mouse background, because the wt
mouse allele, in contrast to the wt rat allele, does contain the PAM
site, which deﬁnes the speciﬁcity of the guide RNA. In addition, the
developing nature of the new-born retina with dividing cells not
yet differentiated into neurons, as discussed above, can only pro-
vide limited information about the effectiveness of such an
approach in mature retinae. Off-target analysis was performed by
Sanger sequencing of eight predicted off-target sites, and no off-
target activity was shown.
5. Future directions
Deciphering the DNA repair status in the retina, and more pre-
cisely in photoreceptor and RPE cells as major target cell types is
crucial before scientists can advance to efﬁcient genome editing
approaches. This knowledge will enable us to control the repair
activities and potentially bias the machinery towards HDR medi-
ated correction of the disease causing mutation. First hints that
inhibition of NHEJ proteins does increase HDR activity, at least
in vitro, point towards the right direction.
A second major point to be addressed represents the safe yet
maximum activity of the designed endonucleases. Absence of
toxicity in terms of off target activity, but also absence of immune
responses to expressed transgenic proteins in retinal cells are
crucial. Experience with a variety of proteins from bacterial and
viral origin in retinal cells and the absence of an immune response
to these proteins in primate models give positive expectations in
this regard (Le Guiner et al., 2007). Genomewide toxicity assays are
required to monitor off target activity of any proposed treatment
approach and represent therefore critical components to the safetytool box for in vivo genome editing.
How about the length of the DNA strand to be corrected/
replaced during the genome editing approach? Especially in
mutational hot spots, such as the ORF15 exon in the RPGR gene,
correction of a large part of this exon or even the entire exonwould
represent a single treatment approach for 80% of all patients with
XLRP. But this would mean to correct almost 2000 bases in one
attempt. There is currently not much known about the factors that
deﬁne the length of DNA that will be corrected, the so-called DNA
conversion tract length. Detailed studies employing different vari-
ants of donor template DNA is warranted to deepen our knowledge
in this ﬁeld.
The ﬁeld of genome editing is a very active one and advances at
rapid pace, potentially addressing many of these challenges in the
near future,. This means that this technologymay yield tremendous
advantages for a large number of patients worldwide even though
major hurdles for successful applications remain to be conquered.
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